{"contentid": 487893, "importid": NaN, "name": "FDA green lights first treatment for molybdenum cofactor deficiency Type A", "introduction": "The US Food and Drug Administration on Friday approved Nulibry (fosdenopterin) for injection to reduce the risk of death due to molybdenum cofactor deficiency Type A, a rare, genetic, metabolic disorder that typically presents in the first few days of life, causing intractable seizures, brain injury and death.", "content": "<p>The US Food and Drug Administration on Friday approved Nulibry (fosdenopterin) for injection to reduce the risk of death due to molybdenum cofactor deficiency Type A, a rare, genetic, metabolic disorder that typically presents in the first few days of life, causing intractable seizures, brain injury and death.</p>\n<p>The FDA granted the approval of Nulibry to Origin Biosciences, an affiliate of BridgeBio Pharma (Nasdaq: BBIO), whose shares gained 8.5% to $70.68 on the news. The FDA accepted the New Drug Application (NDA) for fosdenopterin (previously BBP-870/ORGN001) in September 2020.</p>\n<p>&ldquo;Today&rsquo;s action marks the first FDA approval for a therapy to treat this devastating disease,&rdquo; said Dr Hylton Joffe, director of the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine in the FDA&rsquo;s Center for Drug Evaluation and Research. &ldquo;The FDA remains committed to facilitating the development and approval of safe and effective therapies for patients affected by rare diseases - an area of critical need,&rdquo; he noted.</p>\n<p>Patients with molybdenum cofactor deficiency Type A experience severe and rapidly progressive neurologic damage including intractable seizures, feeding difficulties and muscle weakness from the accumulation of toxic sulfite metabolites in the central nervous system. Most patients die in early childhood from infections. Before today&rsquo;s approval, the only treatment options included supportive care and therapies directed towards the complications arising from the disease, the FDA noted.</p>", "date": "2021-03-01 10:17:00", "meta_title": "FDA green lights first treatment for molybdenum cofactor deficiency Ty", "meta_keywords": "Origin Biosciences, BridgeBio Pharma, Nulibry, Fosdenopterin, FDA, Approval,\nMolybdenum cofactor deficiency Type A", "meta_description": NaN, "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-02-27 15:38:13", "updated": "2021-03-01 10:17:35", "access": NaN, "url": "https://www.thepharmaletter.com/article/fda-green-lights-first-treatment-for-molybdenum-cofactor-deficiency-type-a", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "bridgebio_large.png", "image2id": "bridgebio_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Rare diseases", "topic_tag": "Focus On, One to Watch Companies, Regulation, US FDA", "geography_tag": "USA", "company_tag": "BridgeBio Pharma, Origin Biosciences", "drug_tag": "fosdenopterin, Nulibry", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-01 10:17:00"}